FDA cites Madhu Instruments in New Delhi for insanitary conditions in sterile drug manufacturing and places it on import alert.
What happened
FDA inspected the New Delhi facility from October 11 to 21, 2022. Investigators found sterile-drug manufacturing areas in disrepair, with peeling ceiling paint, a plastic bag over a HEPA filter blocking airflow, broken wall tiles with residue, holes patched with tape, visibly dirty equipment, and stained tape and paper used in filling and packaging. FDA also said the November 11, 2022, response was inadequate and placed the firm on Import Alert 66-40 on May 31, 2023.
What FDA found
Sterile products were made in a facility in disrepair, including peeling ceiling paint, broken wall tiles with residue, and holes patched with tape.
Section 501(a)(2)(A) of the FD&C Act, 21 U.S.C. 351(a)(2)(A)A plastic bag covered a HEPA filter in the manufacturing area and blocked adequate airflow.
Section 501(a)(2)(A) of the FD&C Act, 21 U.S.C. 351(a)(2)(A)Manufacturing equipment was visibly dirty and appeared stained with oil or grease.
Section 501(a)(2)(A) of the FD&C Act, 21 U.S.C. 351(a)(2)(A)A cardboard box used to catch product was lined with stained, soiled masking tape, and printer paper was taped to the work surface for filling and packaging.
Section 501(a)(2)(A) of the FD&C Act, 21 U.S.C. 351(a)(2)(A)The company's cleaning and sanitization procedure was inadequate, and its facility preventive maintenance plan was not properly implemented.
The company's response did not include a retrospective review of product-quality risks, including all potential contamination risks.
What FDA wants
FDA asks for a plan to assess cleaning and disinfection vulnerabilities and facility and equipment design, a plan for routine oversight of facilities and equipment, and documentation of repairs and corrective actions. The company must respond in writing within 15 working days.
Who should pay attention
- companies buying sterile drugs from this manufacturer
- drugmakers relying on Madhu Instruments as a contract manufacturer
- quality teams managing suppliers in India
This is a summary. Read the original letter on fda.gov.